ClinicalTrials.gg
CompletedNCT03766295Updated Dec 8, 2020

Masitinib Plus Gemcitabine in Pancreatic Cancer

A Phase 3 interventional study of Masitinib and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer, sponsored by AB Science. Completed at 9 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-08.

Sponsored by AB Science · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2020, 5 years 11 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Dec 2020.
  • Registered 4 years 5 months after the study started (first participant enrolled Jul 2014, registered Dec 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
377
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 234 studies in Pancreatic Neoplasms with a site in France — 52 open to participants now, 74 under way, 11 of them phase 3. Pancreatic Neoplasms · France.

Enrollment
39th of 181
377 · median 150
Started
2014
with 7 others
Phase 3
42 of 234
4 open now
Registered
124th of 234
by date

Among the 234 studies in Pancreatic Neoplasms with a site in France, this one is the 39th largest by enrollment of the 181 interventional ones that give a count, is one of 8 that started in 2014, is one of 42 in phase 3, and was the 124th registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

52 of the 234 studies in Pancreatic Neoplasms with a site in France are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 234 studies in Pancreatic Neoplasms with a site in France, or all of them as a file.
02

Study summary

The objective is to compare efficacy and safety of masitinib in combination with gemcitabine to placebo in combination with gemcitabine, in treatment of patients with locally advanced or metastatic pancreatic cancer and who have pain related to the disease.

Read the detailed description

Masitinib is a selective tyrosine kinase inhibitor that is thought to promote survival via modulation of immunostimulation-mediated anticancer effects and modulation of the tumor microenvironment. The objective of this study is to evaluate the efficacy and safety of masitinib in combination with gemcitabine with respect to placebo in combination with gemcitabine for the treatment of non resectable locally advanced or metastatic pancreatic cancer patients with pain related to the disease. Approximately 330 patients with pain Visual Analogue Scale (VAS) > 20 and/or treated with 'opioid analgesics' dose ≥ 1 mg/kg/day at baseline will be randomized in a 2:1 ratio to the masitinib and placebo arms, respectively. The primary outcome measure is overall survival (OS).

03

Conditions studied

  • Locally Advanced or Metastatic Pancreatic Cancer

Keywords

  • Pancreatic cancer
  • tyrosine kinase inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main inclusion criteria:

  1. or cytologically confirmed adenocarcinoma of the pancreas, non resectable locally advanced or stage
  2. Patient with pain related to the disease, as assessed by the investigator and the patient:

    • Pain related to the disease as assessed by the investigator is defined as clinical and documented evaluation by the investigator during physical examinations at screening and/or baseline.
    • Pain, as assessed by the patient is defined as at least one value out of two values > 20mm on Visual Analogue Scale at screening or baseline. Visual Analogic scale consists in the visual representation of pain amplitude as perceived by the patient. The amplitude is represented by a 100 mm long line having no reference marks. One extremity indicates an absence of pain (0 value) and the other the worst imaginable pain (100 value).

OR

  • Patient treated with opioid analgesics at a dose ≥ 1 mg/kg/day (morphinic equivalent).
  1. Chemotherapy naïve patient for the advanced/metastatic disease

Main exclusion criteria:

  1. Patient with no pain related to the disease (as defined in the inclusion criterion number 2)
  2. Pregnant or nursing female patient
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
377 participants (actual)

Study arms

  • Experimental
    Masitinib & gemcitabine

    Participants receive masitinib (6 mg/kg/day), given orally twice daily, plus gemcitabine at 1000mg/m2 by intravenous infusion during 30 minutes, once every 7 days, for up to 7 weeks, followed by a week of rest. Subsequent cycles should consist of an IV infusion, once every 7 days, for 3 consecutive weeks out of every 4 weeks, until disease progression, death, limiting toxicity or patient consent withdrawal.

    Drug: Masitinib · Drug: Gemcitabine

  • Active comparator
    Placebo & gemcitabine

    Participants receive matching placebo, given orally twice daily, plus gemcitabine at 1000mg/m2 by intravenous infusion during 30 minutes, once every 7 days, for up to 7 weeks, followed by a week of rest. Subsequent cycles should consist of an IV infusion, once every 7 days, for 3 consecutive weeks out of every 4 weeks, until disease progression, death, limiting toxicity or patient consent withdrawal.

    Drug: Gemcitabine · Drug: Placebo

Interventions

  • Also known as: AB1010

  • Also known as: Gemzar

  • DrugPlacebo

    Also known as: Placebo Oral Tablet

06

What researchers measure

Primary outcomes

  1. Overall Survival (median)

    Overall survival is defined as time in months from the randomization date to the date of death due to any cause. If a patient is not known to have died, then OS will be censored at the date of last known date patient alive.

    Time frame: From day of randomization to death, assessed for a maximum of 60 months

Secondary outcomes

  1. Survival rates

    The proportion of patients alive at each time point, estimated with Kaplan-Meier distribution

    Time frame: every 24 weeks

  2. Progression Free Survival

    Progression Free Survival (PFS) is defined as the time from the randomization date until the date of earliest evidence of disease progression or death, for participants who progressed or died before subsequent cancer therapy. Disease progression will be assessed by the investigator on CT scan according to RECIST 1.1 criteria

    Time frame: From day of randomization to disease progression or death, assessed for a maximum of 60 months

07

Study locations

9 sites
  • Hospital AZ Sint-Jan
    Brugge, 8000, Belgium
  • Polyclinique de Limoges site CHENIEUX
    Limoges, 87000, France
  • Centre Hospitalier de Longjumeau
    Longjumeau, 91160, France
  • General University Hospital of Patras
    Patras, 26504, Greece
  • Sanjeevani CBCC USA Cancer Hospital
    Raipur, 492001, India
  • Omsk Clinical oncology dispensary Omsk
    Omsk, 644013, Russian Federation
  • National Oncology Institute
    Bratislava, 833 10, Slovakia
  • Institut Salah Azaiez de Cancerologie
    Bab Saadoun, Tunisia
  • Center of Surgical Innovations
    Kiev, Ukraine
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2014 to primary completion in Dec 2020, 77 months.

Of 84 phase 3 interventional studies under Pancreatic Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 77. This study's 77 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2018
First posted
Dec 6, 2018
StartActual
Jul 2014
Primary completionActual
Dec 2020
CompletionActual
Dec 2020
Results delay requested
Dec 7, 2020
Last update
Dec 8, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03766295
Lead sponsor
AB Science
Responsible party
Sponsor
First posted
Dec 6, 2018
Start date
Jul 2014
Primary completion
Dec 2020
Completion
Dec 2020
Last update
Dec 8, 2020

Study contacts

Joël Ezenfis, MD
principal investigator · Centre Hospitalier de Longjumeau, France

Oversight

FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Masitinib

Start the discussion